Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Gadolinium Dose in Contrast-Enhanced Breast MRI
2024-518549-27-00Phase 4Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of gadoterate meglumine in breast cancer, sponsored by Radboud University Medical Center. Primary endpoints: Qualitative Evaluation of image quality and Quantitative Evaluation of image quality. Planned start Aug 2025; status: authorised.
02
Drugs
gadoterate meglumine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-518549-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518549-27-00.